Clinical Expression Factors of End-Of-Dose Failure by Controlled-Release Oxycodone in Cancer Patients

Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)
doi 10.5649/jjphcs.40.222
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Japanese Society of Pharmaceutical Health Care and Sciences

Related search

Perbedaan Pengaruh Morphin Controlled Release 30 Mg Dan Oxycodone Controlled Release 20 Mg Oral Terhadap Nyeri Kanker

Jurnal Anestesi Perioperatif
2017English

Cancer and Patients With End-Stage Renal Failure.

BMJ
1982English

Clinical Effects of Combined Treatment by Optimal Dose of Furosemide and Spironolactone on Diastolic Heart Failure in Elderly Patients

Experimental and Therapeutic Medicine
MedicineCancer ResearchImmunologyMicrobiology
2015English

Clinical Characteristics and Risk Factors of 27 Liver Failure Patients Complicated by Invasive Fungal Infections

Health
2011English

Clinical Trials in Acute Heart Failure: Beginning of the End or End of the Beginning?

European Journal of Heart Failure
Cardiovascular MedicineCardiology
2017English

The CardioMEMS System in the Clinical Management of End-Stage Heart Failure Patients: Three Case Reports

BMC Cardiovascular Disorders
Cardiovascular MedicineCardiology
2018English

Bioinspired Heparin Nanosponge Prepared by Photo-Crosslinking for Controlled Release of Growth Factors

Scientific Reports
Multidisciplinary
2017English

Clinical Impact and Associated Factors of Delayed Ambulation in Patients With Acute Heart Failure

Circulation Reports
2019English

Pain Therapy With Oxycodone/Naloxone Prolonged-Release Combination:

Wspolczesna Onkologia
OncologyRadiologyNuclear MedicineImaging
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy